A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Response of Guselkumab in Adult Participants With Celiac Disease
Latest Information Update: 07 Feb 2022
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 20 Jan 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 03 Aug 2021 Planned End Date changed from 25 Dec 2022 to 6 Feb 2023.
- 05 Jul 2021 Status changed from not yet recruiting to recruiting.